INTRODUCTION
Lithium is the cornerstone in the treatment of a manic episode and in the prophylaxis against mood swings in bipolar affective disorder. Its efficacy in this respect is well established. In India, lithium is usually given daily in two or three divided doses while in many European countries a single daily dose is the preferred regimen (Grof et al, 1980; Schouetai, 1982; Kehoe&Mander, 1992; Bramble, 1992) . Whereas currently trials are being conducted on the usefulness of lithium administration on alternate days (Jensen et al, 1990) , it is paradoxical that most of the psychiatrists in our country are not even using single dose lithium therapy.
In this study, we therefore compared acutely manic subjects receiving single dose lithium with those receiving divided dosage in order to assess differences, if any, in terms of efficacy and adverse effects. The main hypothesis addressed was that once daily lithium would be associated with equivalent therapeutic outcome and equivalent or fewer side effects compared to divided dose lithium.
MATERIALS AND METHODS
This study was a retrospective chart review of patients from a single clinical unit in an urban, teaching, postgraduate psychiatric institute. Subjects who had registered between January 1991 and December 1992, who met the DSM-IIIR (American Psychiatric Association, 1987) criteria for acute mania, and who were on therapeutic lithium, were included. Since a rater would have to systematically sift through reams of case notes, it would be impossible for him to remain blind to the lithium dosage schedule. Hence, the charts were evaluated by not one but three raters (KPS, RM & KMRP).
All decisions were based on mutual agreement, and data were recorded on a semi-structured proforma. It was hoped this process would reduce potential bias, if any, in ratings.
Seventy nine subjects met the study criteria; of these, 39 had received single dose lithium and 40 had received divided dose lithium. I'iftcen independent variables (demographic and clinical such as age, sex, previous episodes, family history, previous lithium response, symptom profile etc), and eleven dependent variables (lithium dose, serum level, need for additional treatment, adverse drug reactions etc) were studied.
Different variables were operational ized as follows: Lithium dose was defined as the maximum dose (during acute therapy) that was sustained in order to obtain treatment response. The serum lithium level at this dose was recorded. The mean duration of the episode after starting lithium was the time from starting lithium to the onset of euthymia.
Additional treatment was defined as minimal (only SOS injections, during the acute phase). moderate (addition of neuroleptics for a short duration, lithium being the principal drug) and much (neuroleptics / LCT being the principal therapy, with lithium being the adjunct). Adverse drug reactions like gastritis, tremors, polyuria, hypothyroidism etc., were rated only if they were clearly recorded in the case file as being due to lithium. ITie duration of hospitalization was directly read off from the charts; fitness fordischarge in these patients had been based on the clinical judgement of three consultant psychiatrists.
The two groups were compared with respect to the above variables using the Chi square and Rshcr's exact probability two tailed tests for categorical data. and the independent sample t test for quantitative data. The Mann-Whitney U test was used when the assumptions for parametric statistical testing were ' not met.
RESULTS

Sample description:
Subjects who were on single dose lithium (n= 39) had a mean age of thirty one years and the male:fcmale ratio was 7:1. The mean age of divided dose lithium subjects (n = 40) was twenty nine years and the male:female ratio was 1.6:1. Though the mean age in the two groups was comparable, there was a significantly greater proportion of females in the divided dose group.
The two groups were comparable in the total number of affective episodes, but the single dose group had experienced significantly more depressive episodes (Table 1 ). The groups were comparable with respect to family history of affective disorder and of non-affective psychosis and with respect to past history of lithium response. The two Since sex distribution differed significantly between the two groups, the effect of sex on the dependent variables was analyzed to ascertain whether it could have caused a bias. It was found that all dependent measures were independent of sex. Likewise, the greater number of depressive episodes in single dose group was found not to influence the results.
DISCUSSION
The results of the study indicate that single dose lithium is comparable to divided dose lithium therapy in acute mania. These results are in keeping with the results of many other studies (Perry et al, 1981; Muir et al, 1989) . Most studies have looked at the renal side effects of long term lithium therapy in single daily and divided dose regimens. Perry et al (1981) found no significant difference between the two groups with respect to serum half-lives or renal lithium clearance levels and concluded that the average steady state serum lithium concentration is unchanged by conversion to single daily doses. Moreover, if given once daily, a higher 12 hour serum lithium concentration can be achieved, and it is this concentration that is believed to correlate with the therapeutic efficacy of lithium (Amdisen, 1975) . In this study, single dose subjects needed less dose per day compared to divided dose subjects, though the finding did not reach statistical significance.
Studies have shown that the mean exposure to lithium in the two regimens is about the same, if measured as the area under the two different curves of serum lithium per 24 hours. This is due to a diumal variation in renal clearance, which is lower at night (Lauritsen et al, 1981) , when the lithium concentration would be high if the drug were administered in a single evening dose.
Another advantage of single dose lithium at night is that for at least 12 hours during the day, the scrum level falls below the 12 hour concentration, which is believed to decrease the polyuria associated with lithium therapy (Plenge & Mellerup, 1986) .
The majority of adverse drug reactions in our subjects were lithium induced tremors. These occurred less in single dose subjects, thought not to a statistically significant extent. Incidentally, observations of fewer adverse reactions and better acceptance of single dose lithium are similar to those for most other psychotropics, e.g, tricyclic antidepressants. The single most important advantage of single dose lithium is better drug compliance. Taking lithium two or three times a day is obviously less convenient, especially for working individuals, than taking a single night dose. The psychological effects ofbeing rem inded of the presence of a mental illness twice or thrice a day may also be more damaging.
In conclusion, single dose lithium therapy was found to be comparable to divided dose therapy in acute mania. Hence, single dose lithium should be preferred in the management of acute mania, in order to improve compliance and in view of the other potential benefits discussed above.
